Sandoz this week introduced its calcipotriene and betamethasone dipropionate ointment in the United States. It will be the first generic version of Leo Pharma’s Taclonex ointment in the market.
Calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex ointment, was launched in the United States by Sandoz.
Talconex is a vitamin D analogue and corticosteroid combination product used to treat adults with psoriasis vulgaris, which affects approximately 2% of the US population.
“Sandoz is proud to be first-to-market with a generic version of this important therapy,” said Peter Goldschmidt, president of Sandoz US. “This launch further broadens our strong offering of differentiated generic dermatology products.”
Tolmar Inc. owns the Abbreviated New Drug Application for the product and received FDA approval for a generic version. Sandoz will market its calcipotriene and betamethasone dipropionate ointment in partnership with Tolmar.
Talconex produced $96 million in US sales in 2013, according to IMS Health. Sandoz’s generic version will be available in 60-g and 100-g tubes.
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More